Eiger Mountains

Investor Overview

Corporate Profile

Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of rare diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development a...  More >>

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary Eiger to Present at Jefferies 2019 London Healthcare Conference
PALO ALTO, Calif. , Nov. 15, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies
Toggle Summary Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019
- 53% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24 - Median Decline of HDV RNA: -3.4 Log at Week 24 - 95% of Patients Achieve > 2 Log Decline in HDV RNA at Week 24 PALO ALTO, Calif. , Nov. 12, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc.
Toggle Summary Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update
- Successful Pre-NDA and Pre-MAA Meetings for Progeria & Progeroid Laminopathies - Positive Phase 2 LIFT Lambda Combo Data as Late-Breaker at AASLD - First-Ever Phase 3 HDV International D-LIVR Study Enrolling and Dosing - Strong Balance Sheet with $109.9M in Cash & Investments PALO ALTO, Calif.
Toggle Summary Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019
- >50% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24 - Median Decline of HDV RNA: -3.4 Log at Week 24 - 95% of Patients Achieve >2 Log Decline in HDV RNA at Week 24 PALO ALTO, Calif. , Oct. 21, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc.
Upcoming EventsMore >>
More events are coming soon.
What's New
There are currently no items available.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site.